Diabetes News and Research

Latest Diabetes News and Research

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).

20 Oct 2009

Day care center integrates diabetes care for children into its routine as part of ADA settlement

Pine Hills Kiddie Garden of Fort Wayne, Ind., will take necessary steps to ensure that a child's diabetes care is integrated into the usual routine of its day care center and programs as part of a settlement to resolve allegations that it discriminated on the basis of disability, the Justice Department announced today.

20 Oct 2009

Three deaths in Detroit Marathon highlight the importance of greater public awareness about SDC

The tragic deaths of three runners in Sunday's Detroit Marathon underscore how frequently and indiscriminately sudden cardiac arrest strikes Americans, the Sudden Cardiac Arrest Association said today.

20 Oct 2009

Philips launches DirectLife fitness program to deliver health benefits

Philips is delivering on their commitment to be the leader in health and well-being with the launch of Philips DirectLife, a new customized, interactive fitness program that offers a fun and simple solution to people eager to adopt a more active lifestyle.

20 Oct 2009

Rexall Diabetes Starter Kit for newly diagnosed patients

Over 40 per cent of Canadians diagnosed with a life-threatening disease, such as diabetes, feel confused or overwhelmed after leaving their doctor's office, shows a Leger Marketing survey commissioned by the Rexall family of pharmacies.

20 Oct 2009

Uninsured American adults with diabetes or high cholesterol often go undiagnosed and undertreated: Study

new study shows uninsured American adults with chronic illnesses like diabetes or high cholesterol often go undiagnosed and undertreated, leading to an increased risk of costly, disabling and even lethal complications of their disease.

20 Oct 2009

PhRMA report says nearly 1,000 life-changing medicines for diseases affecting women in development

America's pharmaceutical research and biotechnology companies are working on nearly 1,000 life-changing medicines for diseases affecting women, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). The medicines are awaiting approval by the U.S. Food and Drug Administration or are in human clinical trials.

20 Oct 2009

Body composition analysis can help in determining obesity risk

The body mass index (BMI) has long been the yardstick in deciding who is at risk because of their weight. BMI is essentially a measure of density, identifying 'under-' and 'over-weight' risk groups. Recent studies however point towards a more sophisticated approach to the issue.

20 Oct 2009

Data on ULORIC treatment for gout flares presented at the 73rd American College of Rheumatology meeting

Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to <6.0 mg/dL and the frequency of flares with ULORIC- (febuxostat) treatment.

20 Oct 2009

Health Canada approves new Lantus ClikSTAR reusable insulin pen

Health Canada has approved the ClikSTAR reusable insulin pen for use with Lantus, giving patients with diabetes an additional option to safely and effectively achieve and sustain control of their blood sugar levels. The new insulin delivery device was launched today in conjunction with the 20th World Diabetes Congress being held in Montreal, Quebec, making Canada one of the first countries worldwide to launch this state-of-the-art pen.

20 Oct 2009

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-52, the first of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus (SLE).

20 Oct 2009

Diabetes represents a global health threat

The International Diabetes Federation (IDF) released new data today showing that a staggering 285 million people worldwide have diabetes.

20 Oct 2009

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

Amylin Pharmaceuticals, Inc. today announced that new data from its obesity program will be presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, to be held in Washington, D.C. October 24-28. Phase 2 data from the pramlintide/metreleptin combination treatment clinical program will be the subject of a late-breaking oral presentation.

20 Oct 2009

Boehringer Ingelheim's TWYNSTA approved by FDA for the treatment of hypertension

Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved TWYNSTA®, a new highly effective single pill combination therapy of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]). TWYNSTA® is indicated for the treatment of hypertension, alone or with other antihypertensive agents, and as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.

20 Oct 2009

Children with history of diabetic ketoacidosis may have memory problems

Children who have had an episode of diabetic ketoacidosis, a common complication of diabetes, may have persistent memory problems, according to a new study from researchers at the UC Davis Center for Mind and Brain.

19 Oct 2009

Encorium Group raises $1.6 million through private placement

Encorium Group, Inc., a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced that it has completed a private placement of 3,937,500 shares of its common stock with a private investor for an aggregate purchase price of $1,575,000, or $.40 per share.

19 Oct 2009

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.

19 Oct 2009

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting.

19 Oct 2009

Update from Endo Pharmaceuticals regarding its New Drug Application for FORTESTA

Endo Pharmaceuticals today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for FORTESTA(TM) (testosterone) 2% Gel for men diagnosed with low testosterone (Low T), also known as hypogonadism.

19 Oct 2009

Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it has initiated activities intended to complete the clinical development of the growth hormone secretagogue (GHS) / ghrelin agonist compound macimorelin (AEZS-130) which could be the first oral diagnostic test approved for growth hormone deficiency (GHD). Macimorelin is the International Non-proprietary Name (INN) designated for the compound by the World Health Organization (WHO).

19 Oct 2009

Diabetes News and Research

Latest Diabetes News and Research

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Day care center integrates diabetes care for children into its routine as part of ADA settlement

Three deaths in Detroit Marathon highlight the importance of greater public awareness about SDC

Philips launches DirectLife fitness program to deliver health benefits

Rexall Diabetes Starter Kit for newly diagnosed patients

Uninsured American adults with diabetes or high cholesterol often go undiagnosed and undertreated: Study

PhRMA report says nearly 1,000 life-changing medicines for diseases affecting women in development

Body composition analysis can help in determining obesity risk

Data on ULORIC treatment for gout flares presented at the 73rd American College of Rheumatology meeting

Health Canada approves new Lantus ClikSTAR reusable insulin pen

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Diabetes represents a global health threat

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

Boehringer Ingelheim's TWYNSTA approved by FDA for the treatment of hypertension

Children with history of diabetic ketoacidosis may have memory problems

Encorium Group raises $1.6 million through private placement

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

Update from Endo Pharmaceuticals regarding its New Drug Application for FORTESTA

Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Diabetes News and Research

Latest Diabetes News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in